Bicycle Therapeutics plc (BCYC) News
Filter BCYC News Items
BCYC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BCYC News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BCYC News From Around the Web
Below are the latest news stories about BICYCLE THERAPEUTICS PLC that investors may wish to consider to help them evaluate BCYC as an investment opportunity.
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, England & BOSTON, January 09, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate at the 43rd Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a question-and-answer breakout session at 5:35 p.m. PT. |
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, England & BOSTON, January 03, 2025--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on January 2, 2025, the Compensation Committee of the company’s Board of Directors granted to 12 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 67,300 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering i |
First Solar, Frontier Communications, and More Stocks See Action From Activist InvestorsActivists report to the SEC on First Solar, Bicycle Therapeutics, Garrett Motion, Frontier Communications, nCino, and Ormat Technologies |
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer PatientsOn Thursday, Bicycle Therapeutics plc (NASDAQ:BCYC) announced that it presented data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium. The company revealed topline combination data for zelenectide pevedotin plus Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial ca |
We're Hopeful That Bicycle Therapeutics (NASDAQ:BCYC) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene AmplificationCAMBRIDGE, England & BOSTON, December 12, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium (SABCS) in San Antonio, Texas. The |
Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology ExpertsCAMBRIDGE, England & BOSTON, December 10, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of three new distinguished global oncology experts to its Clinical Advisory Board (CAB) to support the advancement of the company’s clinical oncology programs. |
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program UpdateCAMBRIDGE, England & BOSTON, November 25, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer (TNBC) patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Cancer Symposium (SABC |
Is Bicycle Therapeutics plc (BCYC) Top Performing European Stock Heading into 2025?We recently published a list of 10 Top Performing European Stocks Heading into 2025. In this article, we are going to take a look at where Bicycle Therapeutics plc (NASDAQ:BCYC) stands against other top performing European stocks. As per Deloitte, inflation in the Eurozone slightly rebounded in October but was still quite low. The consumer price index […] |
Bicycle Therapeutics to Participate in the Jefferies London Healthcare ConferenceCAMBRIDGE, England & BOSTON, November 12, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Nov. 19, 2024, at 10:30 a.m. GMT. |